Bart Van Hooland

Bart Van Hooland General Information

Biography

Mr. Bart Van Hooland serves as a Partner at Thia Ventures. He served as a Board Member at Cristal Therapeutics and UFraction8. He was a Co-Founding Partner of Droia Oncology Ventures. He served as a Board Member at Ambagon Therapeutics and Bioncotech Therapeutics, Cyteir Therapeutics. He served as a Board Member at Tusk Therapeutics. He a specialist venture capital investor exclusively focused on oncology. DROIA, based in Luxembourg and Brussels, was co-founded by him in 2011. Prior to that, he worked at the Boston Consulting Group in Paris and was a partner in a number of private holding companies. He acted as interim CEO for two of Droia's portfolio companies, including the creation of former portfolio company Tusk Therapeutics, which was acquired by Roche in 2018. He is a Director on the Boards at Bioncotech, Cristal Therapeutics, and Convert Pharmaceuticals. He graduated as an engineer from the University of Ghent and has an MBA from INSEAD. He worked as a strategy consultant at BCG in Paris and Brussels and has since been the owner, manager, and director of several companies before co-founding Droia. He is a member of the Board of Directors of Gimv, a Euronext-listed private equity and venture capital investor. He is also on the Advisory Board of the Hermes Fund, which has succeeded IWT, the Flemish agency for innovation through science and technology, where he was a Director, and of PMV, the investment company of the Flemish government. GIMV, IWT, and PMV have been instrumental in the development of the Belgian biotech ecosystem.